StemCell Therapy

OMICS International welcomes all the attendees, speakers, sponsors and other research expertise from all over the world to theInternational conferenceon Clinical and Molecular Genetics (Clinical Genetics 2016)which is going to be held duringNovember 28-30,2016inChicago, USA.We are very much honored to invite you all to exchange and share your views and experience on theCurrent Advancements and Novel Research on Genetics at Clinical and Molecular level.

Clinical and molecular geneticsare involved in the diagnosis and management ofhereditary disorderswhich determines the safety and effectiveness ofmedications,devices,diagnostic productsandtreatment regimenswhich are intended for human use and also be used for prevention, treatment, diagnosis or for relieving symptoms of a disease. There is a rapid growth in the field of Clinical and Molecular Genetics because of the increased prevalence of infectious diseases, causative mutating organisms which led to the discovery of novel clinical and genetic testing methods. TheGenetic testingmarket sale is estimated to reach $25 billion annually by 2021 with a growth rate of 10% in the United States. The genetic testing market is believed to reach approximately $60 billion by 2020 globally. US represent the largest market for genetic testing worldwide.

Track -1:Mendelian Genetics: Past and the future

For thousands of years there were lot of questions about genetics and people followed different processes to produce hybrids of different plants and animals. But most of their trails failed as the actual mechanism behind it was unknown. ThereafterMendelwas the first to explain the concept of heredity after experimenting on pea plant (Pisum sativum)through his laws. He proposed Law of Segregation where only one allele pass from parent to offspring as the allele of parents gets separated ,Law of independent Assortment where different pairs of allele passes from parents independently, Law of Dominance where some alleles are dominant the remaining are recessive. Based on this, several hypotheses were proposed later.

Currently there are vast advancements in the field of genetics where researches are focusing on the different diseases caused by variations in genes and many institutions are investing in the research. For example, US government, along with NIH funded Human Genome project based onDNA sequencingtechnologies. Due to the development of new techniques in Bioinformatics there is a huge decrease in the price of genome sequencing, from $100 million to $1000.

The involvement of genetics in heart diseases, cancer and other implications remained far from clear. There are possibilities of practicing human cloning, eugenics apart from these genetic advancements.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-2:Clinical Genomics

Clinical genomics is the use ofgenomic sequencingin clinical basis like for diagnosis, treatment of disease caused in patients. It is a new and rapidly changing field. The diseases like cystic fibrosis and sickle cell anaemia, which are caused by a single base pair change to DNA sequencing, these mutations can be corrected by CRISPR/ Cas technology.

Cas technologyis based on genome editing which is proposed by Editas Medicine with an investment of about $43million. Researchers adopted this technique as most of the microbes use protein and RNAs against invading viruses. The technique involves the editing of stretches in DNA and also to edit single base pairs of the human genome. It was also believed to cure untreatable diseases possibly.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-3:Oncogenomics and Therapeutics

Oncogenomics is the study of the relationship between cancer and the genome of an individual. Its goal is to identifyoncogenesfor the diagnosis and treatment of cancer. Cancer is a genetic disease as it is caused by genetic variation in DNA.NIH offers about $7.4 billion on research related to genetics and about $5.8 on cancer related research. The various techniques used are DNA sequencing, microarray, digital karyotyping, bacterial artificial chromosome.

The American Cancer Society reported that among 1.5 million cases half a million die from the disease mostly of breast cancer, lung cancer, bladder cancer, leukemia. The expenditure on cancer care in 2010 was $125 billion and is estimated to reach $156 billion by 2020 in US.US occupies seventh place inbreast cancerworldwide.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track- 4:Clinical Epigenetics

Clinical epigenetics uses the techniques involved in molecular biology to detect the alterations in DNA methylation or histone modification to diagnose disorders produced by heritable defects in thegene expression. DNA methylation involves in the addition of methyl groups to adenine and guanine bases. DNA is useful for cell development and when methylation occurs on CpG dinucleotide where cytosine precedes guanine suppresses the gene regulation. The nucleosome consists of historians where the tails of histone protrude from nucleosome and therefore they can be modified. The chemical groups attract activating or suppressing complexes to chromatin, which affects its shape, making it more or less available for gene expression. Epigenetic enzyme marketing consists of DNA-modifying, RNA-modifying, Protein is modifying Enzymes which is expected to reach a high rate by 2019. Bisulfite conversion kits; ChIP- seq kits; RNA sequencing kits; whole genome amplification kits are some of the epigenetic kits among which ChIP-seq kits segment had the biggest share in 2014.The market value ofepigeneticswas $413.24 million in 2014, it is expected to reach a CAGR of 13.64% from 2014 to 2019 and it is estimated to grow $783.17 million by 2019 globally.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-5:Regenerative biology and Stem Cell research

Regenerative biology involves the restoration or renewal of damaged genes, cells, tissues, organisms or ecosystem that is produced by some natural fluctuations.Regenerationis mediated by gene regulation and it may be complete (same as old tissue) or incomplete (fibrosis). The market value for tissue engineering and regeneration products was $55.9 billion in 2010 and $59.8 billion in 2011, and is expected to reach $89.7 billion by 2016 at a CAGR of 8.4% globally. According to the reports, the market value of regenerative medicine was about $2.5 billion in the US.

Stem cells are undifferentiated biological cells that undergo mitosis to produce more cells, which are found in multicellular organisms. They are of two types, embryonic and adult stem cells. The stem cell treatment was found to be a lifesaving treatment for the patients with solid tumors and blood disorders.Stem cellscan be obtained from the umbilical cord after babys birth. Possibly they can also be obtained from peripheral blood and bone marrow. According to the reports, in US the availability of stem cell therapy was $15.2 million in 2007 and $16.5 million in 2008 and it is estimated to reach $11 billion by 2020.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-6:Microbial and Human Genetics

There are millions of microorganisms that have a rapid impact on our health. They play a vital role in maintaining the health as well as in the onset of diseases.

Genomics applies DNA sequencing methods andBioinformaticsto analyze the structure and function of genomes. It started from bacteriophage but was overtaken by bacterial genomics. Its applications were included in the fields of medicine, biotechnology and social sciences.

Proteomics is the study of the structure and functions of proteins as they are the essential components of the various metabolic pathways of cells. It is more complicated when compared to genomic studies as it varies from cell to cell.Mass spectroscopyand microarray techniques are mostly used to study proteins presently.

The global market for DNA sequencing products and services in 2012 was $3.5 billion and $4.5 billion in 2013. It is expected to reach $11.7 billion by 2018 with a CAGR of 21.2%.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-7:Next Generation Sequencing

Next Generation Sequencing is a novel method for sequencing DNA and RNA more rapidly, which has made the study of genomics easy. It is the most versatile tool for medical and biological research. The techniques involved are Illumina sequencing, Roche 454 sequencing, Ion torrent: proton sequencing,Solid sequencing. Illumina sequencing is based on DNA colonies or clusters that involves in the clonal amplification of DNA on a surface.454 pyro sequencing amplifies DNA in side water droplets in an oily solution. Ion torrent sequencing is based on using sequencing chemistry with semiconductor based detection system. It is based on detection of hydrogen ions used during polymerisation of DNA whereas solid sequencing involves sequencing by ligation. The NGS market reached $231.7 million in 2012 and $510.7 million in 2013 and is expected to reach $7.6 billion by 2018 with a CAGR of 71.6% globally.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-8:Clinical metabolics and Lipidomics

Lipids are the major components of biological membranes as well as the metabolites of organisms. Lipids play crucial role in biology. Imbalance in the lipid molecules leads to numerous diseases like atherosclerosis, obesity, diabetes, andAlzheimer's disease. Lipidomics is a system-based study of all lipids, which aims at the analysis of lipids in the biological system. Lipidomics is the main tool for potential biomarker discovery, diagnosis the disease and to understand disease pathology mainly in the fields of neurodegeneration, psychiatry, oncology, metabolic diseases, and infectious diseases. The global biomarkers market was $29.3 billion in 2013 and is expected to grow $53.6 billion in 2018 at a CAGR of 12.8%.

Clinical metabolomics is the major and the most powerful tool to screen metabolites in the biological samples. These provide predictive and prognostic biomarkers which are useful to monitor disease states and to improve therapeutic levels. Discovery of biomarkers to differentiate diseases at molecular levels is a difficult task as the metabolite profile is related to the phenotype of an organism;metabolomicsprovide a better understanding of systemic diseases. Metabolomics is also practiced in crop breeding, toxicology, plant biotechnology. The market value for metabolomics was $712 million in 2012 and is expected to reach nearly $1.4 billion in 2017 at a CAGR of 14.2% globally.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-9:Medical and Developmental genetics

Right from the zygote to a developed individual every process is regulated by genes. Developmental genetics is concerned with the process in which genes regulate the development. It is the study of cell fate, cell determination and embryonic development. There are many theories proposed and among them differential gene expression is the most accepted one. The ability to produce an organism from cells is called totipotent, unipotent stem cells produce a family of related cells. Pluripotent and multipoint produce only few organs or tissues, but all these cells forms, acell lineagewhose differentiation can be done by a master control gene. Likewise immune cells are produced from bone marrow; B-cells are responsible for antibody production. By Invivo production of B-cells, antibody diversity can be achieved as process follows differential gene expression. The prenatal and newborngenetic testingmarket were $1.12 billionin 2012 and expected to grow $8.37 billionin 2019 at a CAGR of 26.9% from 2013 to 2019 globally.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-10:Genetic Syndromes and Related Disorders

Genetic disorder is a genetic problem which is associated with the abnormalities in the genome, it may or may not be heritable. For example, cancer can be caused by some inherited genes or by newmutationsor it may be environmental cause in some patients. There are many genetic disorders among them Single-gene disorder is the one which is the resultant of a single mutated gene. It includes diseases like Cystic fibrosis,Sickle-cell-anemia, Polycystic kidney disease, Hemophilia-A, Albinism. Multifactorial diseases include diabetes and heart diseases. Most of the genetic disorders can be identified at birth or in childhood like Huntingtons disease. Treatment for these genetic disorders is still a battle where around 1800 clinical trials have been completed. Presently Gene therapy is followed in which a new gene is introduced to a patient which is very complicated. The market value of products to treatgenetic disorderswas $12.8 billion in 2009 and $17.3 in 2014 globally.

The market value for cancer treatment was about $51.2 billion in 2014 and is expected to reach $66.4 billion by 2019, with a CAGR of 5.4% from 2014 to 2019 globally.The autism spectrum disorders(ASD) market was about $346.2 million in 2013 and $360.9 million in 2014. The market value is expected to grow to $412.7 million by 2019, with a CAGR of 2.7 %.

Related Conferences:

World congress on Human Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling and Genomics Medicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility and Immunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics & Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference on Cancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China; DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Track-11: Genetics Market:

While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future. Many expressed opinions that genetic services will make significant contributions to prediction, detection, and care selection, leading to better quality care and increased affordability. Available genetic tests and genomic applications, can be categorized according to their clinical method of use across prediction, detection, and care selection. The prenatal and newborngenetic testingmarket were $1.12 billionin 2012 and expected to grow $8.37 billionin 2019 at a CAGR of 26.9% from 2013 to 2019 globally.

Related Conferences:

World congress onHuman Genetics, October 31 - November 02, 2016 Valencia, Spain; International Conference on Genetics Counseling andGenomicsMedicine, Aug 11-12, 2016 Birmingham, UK; International conference on Histocompatibility andImmunogenetics, November 28-30, 2016 San Antonio, USA; 6thInternational Conference on Genomics &Pharmacogenomics, September 12-14, 2016, Berlin, Germany; 5th International Conference onCancer Genomics, Aug 8-9, 2016 Las Vegas, USA; 5thGeneticsand Genomics Conference, June 1-3, 2016, Nanjing, China;DNA Damage, Mutation & Cancer, March 13-18, 2016, Ventura, USA; Chromatin andEpigenetics, 20 March 2016, Dubrovnik, Croatia; Chromatin,Non-coding RNAsand RNAP II Regulation in Development and Disease Conference, 29 March 2016, Austin, USA; Maintenance ofGenome Stability2016, March 7-10, 2016, Panama, Central America

Cell Therapy-2015

OMICS International Conferencessuccessfully hosted its premier4thInternational Conference and Exhibition on Cell & Gene Therapyduring August 10-12, 2015 at Crowne Plaza London-Heathrow, London, United Kingdom.

The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.

Cell Therapy-2015is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.

OMICS InternationalConferenceswishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partnersfor their promotion to make this event a huge success.

This4thInternational Conference and Exhibition on Cell & Gene Therapybased on the themeGenomic therapies from base pairs to bedsidewhich covered the below scientific sessions like Cell and Gene Therapy: Potential Applications, Plant Stem Cell Rejuvenation, Plant Stem Cells: Human Therapeutics, Stem Cell Therapies, Cellular Therapies, Advanced Gene Therapeutics, Molecular basis of epigenetics, Cancer Therapies, Nano-Therapy, Bioengineering Therapeutics, Clinical Trials and Research in Cell and Gene Therapies, Regulatory and Ethical Issues of Therapies.

The conference was greeted by the conference Moderator:Dr. Andrei Laikhter,Chemgenes Corporation, USA. The support was extended by the Keynote Speaker:Dr. James Koropatnic,Lawson Health Research Institute and Western University;Dr. Anelia Atanassova,BioGlobaX Inc., Canada;Dr. Noriyuki Kasahara,University of Miami, USA;Dr. Robert Hawkins,The Christie Hospital and University of Manchester, UK andDr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA

OMICSInternationalacknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included:Dr. Ajan Reginald,Cell Therapy Limited, UK;Dr. Andrei Laikhter,Chemgenes Corporation, USA;Dr. Vasiliki Kalodimou,IASO Maternity Hospital, Greece;Dr. Geeta Shroff,Nutech Medicworld, India;Dr. Nady Golestaneh,Georgetown University School of Medicine, USA;Dr. James Koropatnick,Lawson Health Research Institute and Western University, Canada;Dr. Robert Hawkins,Christie Hospital and University of Manchester, UK.

This4thInternational Conference and Exhibition on Cell & Gene Therapywas uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2015 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event.

With the enormous feedback from the participants and supporters 4thInternational Conference and Exhibition on Cell & Gene Therapy,OMICS International Conferencesis glad to announce its5thInternational Conference and Exhibition on Cell & Gene Therapy(Cell Therapy-2016) event from May 19-21, 2016 at San Antonio, USA

- See more at: http://cellgenetherapy.conferenceseries.com/#sthash.npJGo7Qv.dpuf

OMICS International Conferencessuccessfully hosted its premier4thInternational Conference and Exhibition on Cell & Gene Therapyduring August 10-12, 2015 at Crowne Plaza London-Heathrow, London, United Kingdom.

The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.

Cell Therapy-2015is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.

OMICS InternationalConferenceswishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partnersfor their promotion to make this event a huge success.

This4thInternational Conference and Exhibition on Cell & Gene Therapybased on the themeGenomic therapies from base pairs to bedsidewhich covered the below scientific sessions like Cell and Gene Therapy: Potential Applications, Plant Stem Cell Rejuvenation, Plant Stem Cells: Human Therapeutics, Stem Cell Therapies, Cellular Therapies, Advanced Gene Therapeutics, Molecular basis of epigenetics, Cancer Therapies, Nano-Therapy, Bioengineering Therapeutics, Clinical Trials and Research in Cell and Gene Therapies, Regulatory and Ethical Issues of Therapies.

The conference was greeted by the conference Moderator:Dr. Andrei Laikhter,Chemgenes Corporation, USA. The support was extended by the Keynote Speaker:Dr. James Koropatnic,Lawson Health Research Institute and Western University;Dr. Anelia Atanassova,BioGlobaX Inc., Canada;Dr. Noriyuki Kasahara,University of Miami, USA;Dr. Robert Hawkins,The Christie Hospital and University of Manchester, UK andDr. Paul L. Hermonat, Central Arkansas Veterans Healthcare System, USA

OMICSInternationalacknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included:Dr. Ajan Reginald,Cell Therapy Limited, UK;Dr. Andrei Laikhter,Chemgenes Corporation, USA;Dr. Vasiliki Kalodimou,IASO Maternity Hospital, Greece;Dr. Geeta Shroff,Nutech Medicworld, India;Dr. Nady Golestaneh,Georgetown University School of Medicine, USA;Dr. James Koropatnick,Lawson Health Research Institute and Western University, Canada;Dr. Robert Hawkins,Christie Hospital and University of Manchester, UK.

This4thInternational Conference and Exhibition on Cell & Gene Therapywas uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2015 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event.

With the enormous feedback from the participants and supporters 4thInternational Conference and Exhibition on Cell & Gene Therapy,OMICS International Conferencesis glad to announce its5thInternational Conference and Exhibition on Cell & Gene Therapy(Cell Therapy-2016) event from May 19-21, 2016 at San Antonio, USA

Cell Therapy-2014

3rdInternationalConferenceand Exhibition on Cell & Gene Therapywas held duringOctober 27-29, 2014 at Las Vegas, USAwith a theme Uncover the potential that lies within the cell brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue ofJournal of Stem Cell Research & Therapy.

Cell Therapy-2014opened up new vistas and fostered collaborations in the industry and academia.

The conference was embarked with an opening ceremony followed by a series of lectures delivered by bothHonorable Guestsand members of theKeynote forum. The adepts who promulgated the theme with their exquisite talk were;

Dr. Paul L Hermonat,Central Arkansas Veterans Healthcare System, USA Dr. Peter J Quesenberry, The Warren Alpert Medical School of Brown University, USA Dr. Rafael Gonzalez,DaVinci Biosciences, LLC USA Dr. Paul J Davis, Albany Medical College, USA Dr. Stephen Lin,Thermo Fisher Scientifi c, USA

OMICS Grouphas taken the privilege of felicitatingCell Therapy-2014Organizing Committee, Editorial Board Members, Keynote Speakers and business delegates who supported for the success of this event.

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Cell & Gene and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.Our warm gratitude to our sponsors exhibitors & media partners for associating with the conference.

Cell Therapy-2013

2ndInternationalConferenceand Exhibition on Cell & Gene Therapywas held duringOctober 23-25 2013,atOrlando-FL, USAwith a theme Innovative Strategies in Cell & Gene Therapies brought together the International blend of people from Evolving Cell & Gene Therapies making it the largest endeavour from OMICS Group. All the papers presented at this conference were published in special issue ofJournal of Stem Cell Research & Therapy.

Cell Therapy-2013opened up new vistas and fostered collaborations in the industry and academia.

Excerpt from:
International Conference on Clinical and Molecular Genetics

Wlodek Mandecki, Ph.D. Adjunct Professor Office: ICPH-E350V Tel: 973-972-8963 Lab: ICPH-E430L.1 Tel: 973-972-4679

Email: mandecwl@njms.rutgers.edu

The lab works on a method for acquiring sequence data from single nucleic acid molecules. The approach involves a fluorescence resonance energy transfer assay (FRET) based on molecules involved in protein biosynthesis. The fluorescence signal is acquired from single molecules using a fluorescence correlation spectroscope in several configurations, including measurements in solution and on surfaces. The project's goals are to: (i) perform site-directed labeling with a fluorescent dye and quencher; (ii) optimize the FRET assay; (iii) construct a synthetic template and demonstrate the performance of the system on this template; (iv) investigate nanostructures capable of enhancing fluorescence; (v) study the behavior of single molecules in the system; and (vi) demonstrate the capability of the system to acquire high volumes of sequence data. The method once fully developed will allow fast analyses of many types of nucleic acids. The project is funded by the NIH program on the "Revolutionary Genome Sequencing Technologies - the $1000 Genome".

EF-Tu (green) interacts with tRNA (pink) on the ribosome (not shown). Generated in PyMOL from data in 1mj1.pdb file. In addition, Dr. Mandecki's research interests include the mechanisms of frameshifting in ribosomal translation, phage display, protein structure and function, and innovative techniques in nucleic acid and protein analysis.

Consortium

The project is a collaboration between three investigators at the Department of Microbiology and Molecular Genetics of New Jersey Medical School:

as well as the following institutions and investigators:

University of Pennsylvania:

University of North Texas Health Sciences Center

Originally posted here:
Microbiology & Molecular Genetics - New Jersey Medical School

The Department of Genetics currently has 30 faculty members spanning all career stages including tenured, tenure-track, and research-track faculty. Our faculty are actively engaged in scholarship (conducting research, writing grants and peer-reviewed publications, and presenting research at national and international scientific meetings), teaching (teaching courses at Rutgers, lecturing in outside courses, hands-on teaching of post-doctoral fellows, graduate students, and undergraduate students within our laboratories, and participating in numerous activities aimed at educating the general public about the importance of our research), and service(serving on a wide variety of national and local committees, boards, participating in publication and grant peer-review groups).

The research interests of the 30 faculty members span such important areas as: DNA repair mechanisms, instability of cancer cells, molecular evolutionary processes (e.g. gene duplication, enhancer evolution) and evolutionary genetics, gene expression, cellular mechanisms of learning and memory, fertilization (gamete recognition, adhesion, signaling and fusion), and loss of heterozygosity (LOH) for tumor suppressor genes. Several laboratories are actively engaged in human genetics research including searching for genes linked with disease such as Schizophrenia, Autism, Tourette Syndrome, and Alzheimers disease. Other laboratories are applying molecular genetics techniques to model organisms, such as Caenorhabditis elegans (nematode worm), Drosophila melanogaster (fly), mouse, and Escherichia coli (bacterium), to study basic biological processes. We also have faculty working in computational and statistical genetics. For a complete faculty listing and their detailed research descriptions, see our list of faculty or faculty research page.

Members of the faculty have received competitive research grants from several institutes within the National Institutes of Health (NIH) as well as from the National Science Foundation (NSF), the State of New Jersey Commission on Science and Technology and the Commission on Cancer Research, and private foundations including the National Alliance for Research on Schizophrenia and Depression, the Simons Foundation, Autism Speaks, and the March of Dimes.

Our faculty are solely responsible for teaching several undergraduate and graduate courses at Rutgers and play a major role in other team-taught courses. These courses include Introduction to Cancer, Genetics, Genetics Lab, Genetic Analysis I and II, Seminar in Genetics, Genomes, Topics in Molecular Genetics, Topics in Human Genetics, Evolutionary Genetics, Cancer, Quantitative Biology and Bioinformatics, Introduction to Research in Genetics, General Microbiology, Pathogenic Microbiology, Genetics of Compulsive Behavior, Behavioral and Neural Genetics, and Bacterial Physiology.

Continue reading here:
Faculty - Welcome to the Department of Genetics at Rutgers ...

The Molecular Genetics and GenomicsProgram in the Wake Forest School of Medicine is an interdisciplinary research and PhD training program composed of a diverse group of investigators employing molecular and genetic approaches to biomedical research.

The Program includes molecular biologists from each of the basic science departments of the School of Medicine as well as clinical faculty involved in laboratory research. Participating investigators include faculty from the departments of Biochemistry, Cancer Biology, Neurobiology and Anatomy, Medicine, Microbiology and Immunology, Pathology, Pediatrics, Physiology and Pharmacology, and Surgery. Many program faculty are also members of the Comprehensive Cancer Center of Wake Forest University.

Part of the first-year Molecular & Cellular Biosciences (MCB) track, the objective of the PhD training program is to provide an interdisciplinary curriculum that emphasizes the detailed analysis of fundamental biological processes using the tools of molecular biology and genetics. Individualized programs of study are designed to train students for independent careers in research and teaching. The first year MCB curriculum provides broad exposure to the fundamentals of molecular and cellular biology, biochemistry, and microbiology.

After the completion of the first year in the MCB track, students that select a Molecular Genetics & Genomics research advisor begin specialization in the research area of that laboratory. Areas of active investigation include the genetics of complex diseases, genetic epidemiology, epigenetics, and bioinformatics.

Click here to obtain information on the APPLICATION PROCESS for the Molecular Genetics and GenomicsProgram.

The rest is here:
Molecular Genetics and Genomics Program - Wake Forest ...

The Department of Genetics does not yet have its own graduate program. Faculty in the Genetics department generally belong to the graduate programs of Microbiology and Molecular Genetics or Cell and Developmental Biology. Students wishing to pursue a Ph.D. need to apply through the consolidated Graduate Programs in Molecular Biosciences at Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey - Graduate School of Biomedical Sciences.

Students interested in pursuing a MS degree should contact the individual graduate programs for information.

Additional Information can be obtained from the Administrative Office:

Diane Murano 732-445-3430 This email address is being protected from spambots. You need JavaScript enabled to view it.

Nelson Biology Laboratories 604 Allison Road Rutgers - The State University of New Jersey Piscataway, N.J. 08854-8082

Nelson Biology Laboratories 604 Allison Road Rutgers - The State University of New Jersey Piscataway, N.J. 08854-8082

Jessica Joines, Director of the Genetic Counseling Master's Program This email address is being protected from spambots. You need JavaScript enabled to view it. Phone: (848) 445-9637

Continue reading here:
Graduate Studies in Genetics - Rutgers University

Whether you're seeking a B.S. or a Ph.D. in Microbiology or Molecular Genetics, you'll find our department has broad research strengths ranging from molecular, structural, and computational biology to cellular and pathogenic microbiology. You will have access to a rich course curriculum and research laboratories where experienced and supportive faculty will guide your research and help you sharpen your scientific communication skills.

Our research addresses fundamental questions in eukaryotic and prokaryotic cell and molecular biology, using the methods of microbiology, genetics, biochemistry, bioinformatics, and structural biology. This work bears directly on crucial health-related problems such as cancer, AIDS, and infectious disease. Outstanding institutional core facilities provide access to the latest research technologies. The highly collaborative culture of the department is fostered by cross-departmental meetings and journal clubs on a variety of interdisciplinary topics, including DNA repair, parasitology and microbial pathogenesis, and by cross-college consortia such as the Vermont Center for Immunobiology and Infectious Disease. Learn More

The collaborative and interdisciplinary nature of our research programs means that a prospective graduate student is offered a wide choice of research opportunities. While all of our students take the same core curriculum, in their second year they choose to specialize in one of four advanced concentration areas. Our alumni have gone on to become university professors, journal editors and senior scientists and executives in the biotechnology industry. UVM is located in Burlington VT, consistently ranked one of the best places to live in the USA. Learn more

Unique opportunities await students majoring in Microbiology or Molecular Genetics at UVM. Our program is small, which permits our faculty to give each student the individual attention necessary to help them succeed. Our lecture and cutting-edge laboratory courses are challenging and provide each student with a strong foundation and the confidence to work at the bench. The flexibility of our curriculum is such that students can get credit for summer internships or for performing research in one of the many labs at UVM. Small classes foster long lasting camaraderie among our students: MMG'ers are quick to support each other, suggest study tips or point out where to find the best pizza. A student in MMG is never a face in the crowd; our students receive one-on-one mentoring and more often than not end up achieving more than they thought they could. Learn more

See the article here:
Department of Microbiology and Molecular Genetics at the ...

The molecular genetics research interests are in human population genetics, anthropological genetics, immunogenetics, and the genetics of complex diseases. Ultimate goals surround elucidating questions of human variation, the evolutionary history of genes within populations and how these gene histories are involved in the etiology of complex diseases. While the laboratory's research goals have shared consequences for all humanity, specific interests focus on populations of African ancestry.

Operational Objectives:

1. Develop a SNP database for mapping functional mutations linked to diseases common in African peoples.

2. Utilization of evolutionary history of candidate genes to identify polymorphisms that are associated with diseases.

3. Exploit the linkage disquilibrium generated by admixture in the African American population for gene mapping.

CURRENT RESEARCH PROJECTS

The biological transition of enslaved Africans-to-African Americans is marked by the transition of environmental stresses from Africa to those in the Americas, and to a lesser extent, by The incorporation of non-African genes into the African American gene pool. The transition from the various African environments of origin to the diverse American environments is far from insignificant. The American environment imposed new selective pressures on the Africans. These selective pressures may have favored certain genes while eliminating others. This evolutionary hypothesis has been a controversial explanation for the high incidence of diseases such as hypertension in African Americans. Thus, African American biology has been significantly shaped by periods of intermixture creating high heterogeneity, and selective pressures emanating from the unique and particularly adverse social, economic, and political conditions in the US. All of these factors might contribute to the high incidence of diseases with a significant genetic component such as type 2 diabetes, asthma, hereditary cancer (prostate, breast and lung), and hypertension in African Americans.

Prostate cancer is the most common solid malignancy among men in the United States. African American men have the highest incidence of prostate cancer compared to other ethnic groups. This cohort also appears to present more commonly at an advanced stage with aggressive histology and increased cancer-related mortality. Thus, there is a critical need to explore the etiologic pathways (genetic and environmental factors) that contribute to this disparity. In on of our projects "Genes, environment and prostate cancer in populations of African descent" we seek to understand the relative contribution of allelic variations of candidate genes and environmental factors to determine an individuals risk of prostate cancer. The work is geared towards the African American population, for whom genomic studies are limited. African Americans share a common genetic background with West Africans yet vastly different environments. Comparative genetic and epidemiological research on the two populations reveal potential risk factors. This project will provide a better understanding of gene-gene (epistasis), and gene-environment effects on prostate cancer. At research sites in Washington, DC, Chicago, Illinois, and Benin City, Nigeria the goals of the project are to (1) recruit a well characterized cohort of 1200 cases and controls and collect blood for biochemical and molecular assays, along with diet and other environmental information; (2) use state of the art DHPLC technology to provide a formal evaluation of single nucleotide polymorphism (SNP) variation in 22 candidate genes for prostate cancer (androgen associated genes, apoptosis related genes, and diet related genes); (3) construct a web-based database of the SNPs discovered; (4) determine if haplotypic variation in candidate genes accounts for phenotypic variation in prostate cancer, prostate specific antigen (PSA) levels, and disease progression; and (5) assess whether gene-gene and gene-environment interactions exist by examining if prostate cancer risk is modified after stratification of genetic and/or environmental factors. This is the first study which examines SNP markers within the proposed candidate genes, diet, and other environmental variables in clinically evaluated African and African Americans and which evaluates their relative interactions and contribution, if any, to prostate cancer.

In another project, "Haplotype analyses of X chromosome variants: population genetics and implications for prostate cancer" the goals are to (1) provide a formal evaluation of X chromosome variation and linkage disequilibrium in the African American population, (2) determine the relationship of microsatellite alleles (CAG and GGN repeats) within the androgen receptor with the risk for prostate cancer and (3) exploit the evolutionary history of X chromosome haplotypes in order to determine if differences in X chromosome haplotypes account for phenotypic variation in prostate cancer and prostate specific antigen (PSA) levels.

While the molecular genetic research has shared consequences for all humanity, our specific interests focus on populations of African ancestry. Other areas of immediate interest are molecular evolutionary genetics, and biological anthropology. In another project, "the genetics of human pigmentation," we seek to understand the relative contribution of allelic variations of candidate genes responsible for variation in human pigmentation. Pigmentation is a classic anthropological trait that has been studied objectively using reflectance spectroscopy for over 50 years. Skin pigmentation is likely the trait that shows the largest degree of variability among human populations. That there are such dramatic differences in the levels of skin pigmentation among human populations is almost definite evidence for the action of natural selection. The identification of the genes that determine normal within-population variation in pigmentation and differences between populations is the first essential step in the elucidation of the molecular history of human pigmentation. The goals of this project are to (1) develop a database and sample collection that will allow for the delineation of the genes that determine pigmentation, and (2) genotype these individuals for a number of candidate genes to identify those which determine natural variation in pigmentation.

Mutation analyses of BRCA1 and BRCA2. We are analyzing the breast cancer predisposing genes, BRCA1 and BRCA2, for germline mutations in African American families at high-risk for hereditary breast cancer. Patients are considered high-risk if they have a family history of the disease, early onset breast cancer, bilateral breast cancer, breast and ovarian cancer, or a male affected with breast cancer. The entire BRCA1 and BRCA2 coding and flanking intron regions are being examined for mutation detection. In preliminary studies of BRCA1 using the technique of single strand conformation polymorphism, we identified 11 different germline mutations/ variations in 7 patients from 45 high-risk families. Two pathogenic, protein-truncating mutations were detected in exon 11. A ten base pair tandem duplication, 943ins10, was present in a woman with breast and ovarian cancer whose first-degree relatives had prostate cancer. A four base pair deletion, 3450del4, was detected in a breast cancer patient with five cases of breast cancer in the family; two of the proband's sisters with breast cancer also carried the same mutation. Four amino acid substitutions (Lys1183Arg, Leu1564Pro, Gln1785His, and Glu1794Asp) and four nucleotide substitutions in intron 22 (IVS22+78 C/A, IVS22+67 T/C, IVS22+8 T/A and IVS22+7 T/C) were observed in patients and not in control subjects. One early onset breast cancer patient carried five distinct BRCA1 variations, two amino acid substitutions and three substitutions in intron 22. An amino acid substitution in exon 11, Ser1140Gly, was identified in 3 different unrelated patients and in 6 of 92 control samples. The latter probably represents a benign polymorphism. BRCA1 and BRCA2 analyses for the detection of mutations are ongoing.

Genetic variation in asthma. Asthma families collected by HU investigators were part of the Collaborative Study on the Genetics of Asthma (CSGA) genome-wide search for asthma susceptibility loci in ethnically diverse populations. Asthma is an inflammatory airways disease associated with intermittent respiratory symptoms, bronchial hyper-responsiveness (BHR) and reversible airflow obstruction and is phenotypically heterogeneous. Patterns of clustering and segregation analyses in asthma families have suggested a genetic component to asthma. Previous studies reported linkage of BHR and atopy to chromosomes 5q, 6p, 11q, 14q, and 12q. One genome-wide search in atopic sib pairs had been reported, however, only 12% of their subjects had asthma. The CSGA conducted a genome-wide search in 140 families with > or = 2 asthmatic sibs, from three different populations and reported evidence for linkage to six novel regions: 5p15 (P = 0.0008) and 17p11.1-q11.2 (P = 0.0015) in African Americans; 11p15 (P = 0.0089) and 19q13 (P = 0.0013) in Caucasians; 2q33 (P = 0.0005) and 21q21 (P = 0.0040) in Hispanics. Evidence for linkage was also detected in five regions previously reported to be linked to asthma-associated phenotypes: 5q23-31 (P = 0.0187), 6p21.3-23 (P = 0.0129), 12q14-24.2 (P = 0.0042), 13q21.3-qter (P = 0.0014), and 14q11.2-13 (P = 0.0062) in Caucasians and 12q14-24.2 (P = 0.0260) in Hispanics.

Dermatophagoides pteronyssinus (Der p) is one of the most frequently implicated allergens in atopic diseases. Although HLA could play an important role in the development of the IgE response to the Der p allergens, genetic regulation by non-HLA genes influences certain HLA-associated IgE responses to complex allergens. To clarify genetic control for the expression of Der p-specific IgE responsiveness, a genome-wide search was conducted for genes influencing Der p-specific IgE antibody levels by using 45 Caucasian and 53 African American families ascertained as part of the Collaborative Study on the Genetics of Asthma (CSGA). Specific IgE antibody levels to the Der p crude allergen and to the purified allergens Der p 1 and Der p 2 were measured. Multipoint, nonparametric linkage analysis of 370 polymorphic markers was performed with the GENEHUNTER program. The best evidence of genes controlling specific IgE response to Der p was obtained in 2 novel regions: chromosomes 2q21-q23 (P = .0033 for Caucasian subjects) and 8p23-p21 (P = .0011 for African American subjects). Three regions previously proposed as candidate regions for atopy, total IgE, or asthma also showed evidence for linkage to Der p- specific IgE responsiveness: 6p21 (P = .0064) and 13q32-q34 (P = 0.0064) in Caucasian subjects and 5q23-q33 (P = 0.0071) in African American subjects. No single locus generated overwhelming evidence for linkage in terms of established criteria and guidelines for a genome-wide screening, which supports previous assertions of a heterogeneous etiology for Der p-specific IgE responsiveness. Two novel regions, 2q21-q23 and 8p23-p21, that were identified in this study merit additional study. In addition genome-wide screening was conducted for genes influencing Dermatophagoides pteronyssinus-specific IgE responsiveness as a part of the Collaborative Study on the Genetics of Asthma (CSGA). Evidence for linkage was found in some regions, including chromosomes 5131-q33 and 11q13 in African American families. Plans are underway to initiate an international study of the genetics of asthma in collaboration with medical scientists in Ghana and investigators at the NHGC. These investigations will target regions where associations with specific IgE responses have been indicated in African Americans.

top of page

DEVELOPING PROJECTS

Characterization of African American Ancestral HLA Haplotypes in West Africa.

An important area of investigation at the NHGC is the inclusion of evolutionary history of genes as a diagnostic probe in tracing the history of disease in a population.

This project builds upon the foundation of research on the genetics of complex diseases common in African Americans already established with the NHGRI in partnership with the NIH Office of Research on Minority Health. More specifically, it would build upon African American Diabetes mellitus (AADM) an international human gnome research initiative to map genes for type 2 diabetes in ancestral populations of African Americans. Because of the overlap in clinical phenotype of some subsets of types 1 and 2 diabetes, the rationale for this study is that characterization of HLA class II haplotypes in the west African study population may assist in refining the clinical phenotype of a subset of type 2 diabetes patients.

The association of HLA class II genes with susceptibility to type 1 diabetes is well documented in many populations. In African Americans type 1 diabetes patients, unique HLA class II polymorphisms have been instructive in determining risk assessment of closely linked HLA loci. We have reported the association of a unique HLA-DR3 haplotype in African Americans that appears to be associated with resistance to type 1 diabetes. The higher frequency of this haplotype among controls raises questions about the frequency of this haplotype in west African ancestral populations of African Americans.

The long range goal of research at the NHGC is to improve the health status of African Americans through research on human DNA sequence variation and to apply the knowledge gained to better understand the biomedical significance of gene-based differences already known to exist among populations in the immune response to organ transplants; sensitivity to drugs; influence of environment on health, and susceptibility to complex diseases, such as cancer and diabetes.

The research goals of the molecular genetics component are predicated upon the two broad hypotheses of population variation in DNA polymorphic markers used to map genes and the correlation of population-based variation in DNA polymorphic markers with disease.Studies of human leukocyte antigen (HLA) polymorphisms and other genetic polymorphic systems have consistently shown greater genetic variability in African populations. The biomedical implications of population-based variation in HLA genes are seen in association in the arena of clinical transplantation, where decisions regarding the distribution of limited donor organs must be informed by science and balanced by the ethical concerns of the larger society.

The goal of this study is to define HLA alleles and haplotypes in the study population and determine whether allele and haplotype frequencies in diabetics differ from controls. If a difference is found, the implication of HLA associations with the clinical phenotype of type 2 diabetes will be investigated. The study of HLA haplotypes in west African ancestral populations of African Americans will help identify HLA polymorphisms that are common in this population.Since HLA has been associated with a variety of autoimmune diseases, the results of this study should not only be useful in the analysis of HLA haplotypes in type 2 diabetes, but also informative for population-based HLA evolutionary studies.

top of page

Linkage disequilibrium (LD) in African Americans.

Linkage disequilibrium is a population genetic phenomenon that has been useful for gene mapping efforts. LD can usually be found in populations for genes that are tightly (close genetic distance) linked, and can be generated by mutation, selection, or admixture of populations with different allele frequencies. Generally, disequilibrium is dependent on population size, time (generations), and distance between genetic markers. Normally, the greater the distance between markers, the faster the decay of disequilibrium. The nonrandom association of alleles at different genetic loci can be measured by a variety of linkage disequilibrium measures.

Within the African American population one would expect to find short genomic areas of tight LD, a legacy of this population's roots in the antiquity of African human history, together with large areas of LD, a legacy of more recent admixture with Europeans and Native Americans. Assessment of the level of genetic variation and LD in the African American population is important for several reasons. It will allow us to better understand the mechanisms responsible for the creation and maintenance of LD over genomic regions.

This better understanding will aid in the mapping of genes responsible for complex diseases. We expect to observe a diverse pattern of LD among the African American chromosomes when compared to other populations. While the pattern observed among African Americans is not restricted to the population, it is observed at higher frequency than others with diffferent populatioin histories. African American chromosomes with ancestry in West Africa should exhibit closely linked disequilibrium while chromosomes with ultimate ancestry from Europe will reveal broader regions of disequilibrium. What this study will do is assess patterns and level of LD among chromosomal regions within the African American population.

Significance of the African American population for gene mapping

As stated above, LD can be generated by admixture between divergent populations. Thus, a genetic consequence of the unique population history of African Americans is increased LD. We caution that much of the disequilibrium may not actually be due to genetic linkage, but are artifacts of divergent allele frequencies in the parental populations. However, it is expected that linked loci will also show significant disequilibrium in the African American population. The analysis of LD between marker and disease loci has proven to be a powerful tool for positional cloning of disease genes.

When a disease or trait manifests variation between populations, admixed populations provide a population based approach to evaluate the relative importance of genetic factors. A variety of statistical genetic methods for disease studies exploit the LD created by admixture. These include the Transmission Disequilibrium Test (TDT) and Mapping by Admixture Linkage Disequilibrium (MALD). An important assumption of many of these methods is that the ancestry of alleles at each locus be assigned to one of the two founding populations. The assignment of alleles to parent populations is problematic at times, however as more informative genetic markers are found and more individuals and populations sampled, the statistical power to assign alleles increases.

top of page

RESOURCES

The Molecular Genetics Laboratory in the National Human Genome Center is newly renovated and is located on the 6th floor of the Howard University Cancer Center. This facility is approximately 7,500 square feet. There are two large laboratories (~1500 sq. ft. each), a DNA sequencing and genotyping room (~800 sq. ft.), two cold rooms, dark room, and a walk-in freezer. The laboratory space is equipped with benches, tables, sinks, distilled water, fume hoods and separate areas for tissue culture, PCR, and radioisotope use.

Four Pentium III NT Workstations (400-500 mHz) and four Power Macintosh G4's provide the computational hardware for the Molecular Genetics laboratory. The eight computers are networked together via the Genome Center NT server with the 5 computers operating three ABI 377 DNA sequencers and two DNA Wave Machines in addition to the computers used by the Genetic Epidemiology and Statistical Genetics units. The molecular genetics laboratory contains all the standard equipment necessary for large-scale, high throughput molecular analysis of DNA variation. These items include centrifuges, waterbaths, gel electrophoresis apparatus, pipettes, glassware, balances, etc. The laboratory also has two Transgenomics DNA Wave machines for SNP detection using dHPLC. The genotyping room contains three ABI 377 automated sequencers, ten Perkin Elmer 9700 thermocyclers, and the PSQ 96 Pyrosequencing platform for SNP genotyping.

Molecular genetics laboratory space on the 5th floor of the cancer center, contains two ABI 373 automated sequencers. The immunogenetics core research laboratory, also on the 5thfloor of the cancer center, provides approximately 800 sq ft of additional laboratory space for molecular genetics work.

top of page

CORE SERVICES

The Molecular Genetics Laboratory will utilize current SNP technologies to:

1) identify and characterize DNA sequence variation in the NHGC African American population resource,

2) generate databases for locating functional mutations in candidate genes involved in the biology and pathophysiology of complex diseases common in African Americans and other populations in the African Diaspora,

3) develop a database of allele and haplotype frequencies for a reference panel of SNP variants in the NHGC population resource. This will include a set of candidate genes for complex diseases common in African Americans,

Prostate Cancer

Breast cancer

Asthma

Type 2 diabetes

Hypertension

HIV aids

4) Use coalescence models to construct phylogenies of the candidate genes in order to evaluate the evolutionary history of the genes in various populations. Construct haplotype phylogenies for a reference set of DNA loci/markers representative of various types of polymorphic systems found in the genome. This will include but is not limited to the following:

Single nucleotide polymorphisms (SNPs)

Microsatellites (mono, di, tri, and tetra nucleotide repeats)

Minisatellites (variable number of tandem repeats/VNTRs)

Nucleotide insertions and deletions

Alu repeats

MOLECULAR GENETICS UNIT GROUP PICTURE

06-Jan-2008

top of page

See the article here:
Howard University National Human Genome Center

Nikhat Parveen, Ph.D. Associate Professor Office: ICPH-E350T Tel: 973-972-5218 Lab: ICPH-E-310N.1 Tel: 973-972-4437

Email: parveeni@njms.rutgers.edu

My laboratory is studying the molecular basis of pathogenesis of bacterial species, Borrelia burgdorferi, Treponema pallidum and Pseudomonas aeruginosa. These clinically important bacterial pathogens are transmitted to humans using different mechanisms and also show different disease manifestations. B. burgdorferi is transmitted by Ixodes tick vector, T. pallidum by sexual contact and P. aeruginosa, a ubiquitously present organism, is transmitted through ventilation or by direct contact of the patient with the contaminated source.

B. burgdorferi, a spirochete, is causative agent of Lyme disease, a multisystemic illness that affects various organs including joints, heart, nervous system and skin. If untreated, it may result in chronic disease with the symptoms including arthritis, acrodermatitis or neuroborreliosis. It is an extracellular pathogen often found adhering to the host cells in the biopsy specimens of the patients. We have been studying the molecular mechanisms involved in the attachment of Lyme disease spirochetes to a variety of host cells. The specific interaction between the spirochete and host cells may be responsible for the tissue tropism exhibited by B. burgdorferi. Our objective is to understand whether different B.burgdorferi adhesins show affinity for different host receptors on various host cells. We use genetics, biochemical techniques and tissue culture system to identify and characterize the bacterial and host molecules involved in this interaction in vitro. We have already identified two types of glycosaminoglycan receptors on mammalian cells that are recognized by several B. burgdorferi proteins and we are further characterizing this interaction. Mouse is a natural host of B. burgdorferi and C3H mice show several manifestations of Lyme disease observed in humans. We have recently adapted firefly luciferase-based detection system for B. burgdorferi. Using a combination of bioluminescent B. burgdorferi and mouse model of infection, we will further analyze the contribution of each bacterial ligand-host receptor interaction in Lyme pathogenesis. Tissue colonization by the spirochetes will be monitored non-invasively by employing in vivo imaging system. Recently, we have initiated studies to understand molecular basis of T. pallidum pathogenesis using this as a surrogate system.

P. aeruginosa is an opportunistic pathogen and produces a wide variety of virulence factors. It results in a variety of illnesses and is responsible for high morbidity and mortality in immunocompromised and elderly patients. Due to a highly adaptable nature of P. aeruginosa and its ability to survive even in detergents, it is a major contributor to infections in the hospital environment. We have been studying the quorum-sensing mediated induction of several virulence factors in this organism both as free-living organism and in association with its different hosts. We will assess the role of selected virulence factors in biofilm formation while P. aeruginosa is present in communities along with the other organisms. Our current focus is to investigate genetics of production and regulation of PrpL protease and pyocyanin pigment of P. aeruginosa and examine the roles of these virulence factors in tissue destruction. The roles of these two virulence factors in corneal damage, in burn wounds and in the cystic fibrosis patients will then be examined.

1988-1991 Scientist at IARI, New Delhi and Investigator in Indo-US Bilateral Program

1991-1995 Ph.D. in Microbiology, University of Hawaii at Manoa, Honolulu, HI

1996-Nov.00 Postdoctoral Fellow, mentor: John Leong, Univ. Mass. Med. School, MA

2000-May 05 Research Assistant Professor, Univ. Mass. Med. School, MA

Original post:
Microbiology & Molecular Genetics - Rutgers New Jersey ...

Molecular evolution is a change in the sequence composition of cellular molecules such as DNA, RNA, and proteins across generations. The field of molecular evolution uses principles of evolutionary biology and population genetics to explain patterns in these changes. Major topics in molecular evolution concern the rates and impacts of single nucleotide changes, neutral evolution vs. natural selection, origins of new genes, the genetic nature of complex traits, the genetic basis of speciation, evolution of development, and ways that evolutionary forces influence genomic and phenotypic changes.

The content and structure of a genome is the product of the molecular and population genetic forces which act upon that genome. Novel genetic variants will arise through mutation and will spread and be maintained in populations due to genetic drift or natural selection.

Mutations are permanent, transmissible changes to the genetic material (DNA or RNA) of a cell or virus. Mutations result from errors in DNA replication during cell division and by exposure to radiation, chemicals, and other environmental stressors, or viruses and transposable elements. Most mutations that occur are single nucleotide polymorphisms which modify single bases of the DNA sequence. Other types of mutations modify larger segments of DNA and can cause duplications, insertions, deletions, inversions, and translocations.

Most organisms display a strong bias in the types of mutations that occur with strong influence in GC-content. Transitions (A G or C T) are more common than transversions (purine pyrimidine)[1] and are less likely to alter amino acid sequences of proteins.

Mutations are stochastic and typically occur randomly across genes. Mutation rates for single nucleotide sites for most organisms are very low, roughly 109 to 108 per site per generation, though some viruses have higher mutation rates on the order of 106 per site per generation. Among these mutations, some will be neutral or beneficial and will remain in the genome unless lost via Genetic drift, and others will be detrimental and will be eliminated from the genome by natural selection.

Because mutations are extremely rare, they accumulate very slowly across generations. While the number of mutations which appears in any single generation may vary, over very long time periods they will appear to accumulate at a regular pace. Using the mutation rate per generation and the number of nucleotide differences between two sequences, divergence times can be estimated effectively via the molecular clock.

Recombination is a process that results in genetic exchange between chromosomes or chromosomal regions. Recombination counteracts physical linkage between adjacent genes, thereby reducing genetic hitchhiking. The resulting independent inheritance of genes results in more efficient selection, meaning that regions with higher recombination will harbor fewer detrimental mutations, more selectively favored variants, and fewer errors in replication and repair. Recombination can also generate particular types of mutations if chromosomes are misaligned.

Gene conversion is a type of recombination that is the product of DNA repair where nucleotide damage is corrected using orthologous genomic regions as a template. Damaged bases are first excised, the damaged strand is then aligned with an undamaged homolog, and DNA synthesis repairs the excised region using the undamaged strand as a guide. Gene conversion is often responsible for homogenizing sequence of duplicate genes over long time periods, reducing nucleotide divergence.

Genetic drift is the change of allele frequencies from one generation to the next due to stochastic effects of random sampling in finite populations. Some existing variants have no effect on fitness and may increase or decrease in frequency simply due to chance. "Nearly neutral" variants whose selection coefficient is close to a threshold value of 1 / the effective population size will also be affected by chance as well as by selection and mutation. Many genomic features have been ascribed to accumulation of nearly neutral detrimental mutations as a result of small effective population sizes.[2] With a smaller effective population size, a larger variety of mutations will behave as if they are neutral due to inefficiency of selection.

Selection occurs when organisms with greater fitness, i.e. greater ability to survive or reproduce, are favored in subsequent generations, thereby increasing the instance of underlying genetic variants in a population. Selection can be the product of natural selection, artificial selection, or sexual selection. Natural selection is any selective process that occurs due to the fitness of an organism to its environment. In contrast sexual selection is a product of mate choice and can favor the spread of genetic variants which act counter to natural selection but increase desirability to the opposite sex or increase mating success. Artificial selection, also known as selective breeding, is imposed by an outside entity, typically humans, in order to increase the frequency of desired traits.

More here:
Molecular evolution - Wikipedia, the free encyclopedia

Dr. Jeffrey Noebels, professor of neurology and molecular and human genetics, is leading a new research center of international scientists who seek to answer questions that arise from the mystery of sudden unexpected death in epilepsy (SUDEP).

While you may have tuned into the Grammy awards this month, a smaller group waited at their keyboard to see who would win the 2015 Lab Grammy for Education Video and Song Parody Video of the year awarded by BioTechniques.

What drives innovation? For Dr. Trey Westbrook its a personal mission to find new treatments for invasive breast cancer. His work focuses on the genetic mechanisms and key targets for treating triple-negative breast cancer.

Immigrants make the journey to the United States for a number of reasons. For physician and medical researcher Huda Zoghbi, her journey began with a dangerous war that left her no choice. Growing up in Beirut, Lebanon, Huda could not have been any happier. The citys peaceful and vibrant atmosphere in the 1970s was inviting Continue reading

This feature is part of an ongoingseriesthat focuses on VIICTR.org, highlighting clinical and translational research at Baylor College of Medicine. Dr. Christian Schaaf wants to identify the underlying cause of high-functioning autism. Schaaf, physician-scientist, is an assistant professor of molecular and human genetics at Baylor College of Medicine and a member of the Jan and Continue reading

Baylor College of Medicines genetics program continues to break barriers in diagnosing rare diseases through the use of advanced genome testing. Often the diagnosis is just the starting point for researchers, uncovering a rare disease where little is known and funding to study it is scarce or nonexistent. One family who has benefitted from Baylors Continue reading

Clinicians and scientists from Baylor College of Medicine and Texas Childrens Hospital will become part of a new national network joining forces to address prolonged undiagnosed medical conditions, through the National Institutes of Healths Undiagnosed Diseases Network. It was established to help address the most rare and difficult-to-solve medical cases from around the country and Continue reading

The study of genetics had a different look 50 years ago, and so did the researchers. This Throwback Thursday we take a look back in the careers of Dr. Thomas Caskey, professor of molecular and human genetics, and Dr. Art Beaudet, the Henry and Emma Meyer Chair in theDepartment of Molecular and Human Genetics, through Continue reading

When some professors prepare to step down as chair of a department there can be luncheons, speeches and plaques. For Dr. Arthur Beaudet, the Henry and Emma Meyer Chair in Molecular Genetics Professor and chair of theDepartment of Molecular and Human Genetics, there is singing and cup choreography, too. A riff on the popular Cups Continue reading

Our remarkable faculty received accolades over the past year for their professional achievements, research findings and contributions to medicine and science. Take a look back of the researchers, the awards and other events that happened during 2013. Dr. Kline receives Humanitarian Award Internationally recognized HIV/AIDS specialist, Dr. Mark Kline was honored in April by the Continue reading

Read more:
molecular and human genetics | Momentum - The Baylor ...

Table of Contents

The physical carrier of inheritance | The structure of DNA | DNA Replication

While the period from the early 1900s to World War II has been considered the "golden age" of genetics, scientists still had not determined that DNA, and not protein, was the hereditary material. However, during this time a great many genetic discoveries were made and the link between genetics and evolution was made.

Friedrich Meischer in 1869 isolated DNA from fish sperm and the pus of open wounds. Since it came from nuclei, Meischer named this new chemical, nuclein. Subsequently the name was changed to nucleic acid and lastly to deoxyribonucleic acid (DNA). Robert Feulgen, in 1914, discovered that fuchsin dye stained DNA. DNA was then found in the nucleusof all eukaryoticcells.

During the 1920s, biochemist P.A. Levene analyzed the components of the DNA molecule. He found it contained four nitrogenous bases: cytosine, thymine, adenine, and guanine; deoxyribose sugar; and a phosphate group. He concluded that the basic unit (nucleotide) was composed of a base attached to a sugar and that the phosphate also attached to the sugar. He (unfortunately) also erroneously concluded that the proportions of bases were equal and that there was a tetranucleotide that was the repeating structure of the molecule. The nucleotide, however, remains as the fundemantal unit (monomer) of the nucleic acid polymer. There are four nucleotides: those with cytosine (C), those with guanine (G), those with adenine (A), and those with thymine (T).

Molecular structure of three nirogenous bases. In this diagram there are three phosphates instead of the single phosphate found in the normal nucleotide. Images from Purves et al., Life: The Science of Biology, 4th Edition, by Sinauer Associates (www.sinauer.com) and WH Freeman (www.whfreeman.com), used with permission.

During the early 1900s, the study of genetics began in earnest: the link between Mendel's work and that of cell biologists resulted in the chromosomal theory of inheritance; Garrod proposed the link between genes and "inborn errors of metabolism"; and the question was formed: what is a gene? The answer came from the study of a deadly infectious disease: pneumonia. During the 1920s Frederick Griffith studied the difference between a disease-causing strain of the pneumonia causing bacteria (Streptococcus peumoniae) and a strain that did not cause pneumonia. The pneumonia-causing strain (the S strain) was surrounded by a capsule. The other strain (the R strain) did not have a capsule and also did not cause pneumonia. Frederick Griffith (1928) was able to induce a nonpathogenic strain of the bacterium Streptococcus pneumoniae to become pathogenic. Griffith referred to a transforming factor that caused the non-pathogenic bacteria to become pathogenic. Griffith injected the different strains of bacteria into mice. The S strain killed the mice; the R strain did not. He further noted that if heat killed S strain was injected into a mouse, it did not cause pneumonia. When he combined heat-killed S with Live R and injected the mixture into a mouse (remember neither alone will kill the mouse) that the mouse developed pneumonia and died. Bacteria recovered from the mouse had a capsule and killed other mice when injected into them!

Hypotheses:

1. The dead S strain had been reanimated/resurrected.

See original here:
DNA and Molecular Genetics - Estrella Mountain Community ...

The term molecular genetics is now redundant because contemporary genetics is thoroughly molecular. Genetics is not made up of two sciences, one molecular and one non-molecular. Nevertheless, practicing biologists still use the term. When they do, they are typically referring to a set of laboratory techniques aimed at identifying and/or manipulating DNA segments involved in the synthesis of important biological molecules. Scientists often talk and write about the application of these techniques across a broad swath of biomedical sciences. For them, molecular genetics is an investigative approach that involves the application of laboratory methods and research strategies. This approach presupposes basic knowledge about the expression and regulation of genes at the molecular level.

Philosophical interest in molecular genetics, however, has centered, not on investigative approaches or laboratory methods, but on theory. Early philosophical research concerned the basic theory about the make-up, expression, and regulation of genes. Most attention centered on the issue of theoretical reductionism. The motivating question concerned whether classical genetics, the science of T. H. Morgan and his collaborators, was being reduced to molecular genetics. With the rise of developmental genetics and developmental biology, philosophical attention has subsequently shifted towards critiquing a fundamental theory associated with contemporary genetics. The fundamental theory concerns not just the make-up, expression, and regulation of genes, but also the overall role of genes within the organism. According to the fundamental theory, genes and DNA direct all life processes by providing the information that specifies the development and functioning of organisms.

This article begins by providing a quick review of the basic theory associated with molecular genetics. Since this theory incorporates ideas from the Morgan school of classical genetics, it is useful to sketch its development from Morgan's genetics. After reviewing the basic theory, I examine four questions driving philosophical investigations of molecular genetics. The first question asks whether classical genetics has been or will be reduced to molecular genetics. The second question concerns the gene concept and whether it has outlived its usefulness. The third question regards the tenability of the fundamental theory. The fourth question, which hasn't yet attracted much philosophical attention, asks why so much biological research is centered on genes and DNA.

The basic theory associated with classical genetics provided explanations of the transmission of traits from parents to offspring. Morgan and his collaborators drew upon a conceptual division between the genetic makeup of an organism, termed its genotype, and its observed manifestation called its phenotype (see the entry on the genotype/phenotype distinction). The relation between the two was treated as causal: genotype in conjunction with environment produces phenotype. The theory explained the transmission of phenotypic differences from parents to offspring by following the transmission of gene differences from generation to generation and attributing the presence of alternative traits to the presence of alternative forms of genes.

I will illustrate the classical mode of explanatory reasoning with a simple historical example involving the fruit fly Drosophila melanogastor. It is worth emphasizing that the mode of reasoning illustrated by this historical example is still an important mode of reasoning in genetics today, including what is sometimes called molecular genetics.

Genes of Drosophila come in pairs, located in corresponding positions on the four pairs of chromosomes contained within each cell of the fly. The eye-color mutant known as purple is associated with a gene located on chromosome II. Two copies of this gene, existing either in mutated or normal wild-type form, are located at the same locus (corresponding position) in the two second-chromosomes. Alternative forms of a gene occurring at a locus are called alleles. The transmission of genes from parent to offspring is carried out in a special process of cellular division called meiosis, which produces gamete cells containing one chromosome from each paired set. The half set of chromosomes from an egg and the half set from a sperm combine during fertilization, which gives each offspring a copy of one gene from each gene pair of its female parent and a copy of one gene from each gene pair of its male parent.

Explanations of the transmission of traits relate the presence of alternative genes (genotype) to the presence of alternative observable traits (phenotype). Sometimes this is done in terms of dominant/recessive relations. Purple eye-color, for example, is recessive to the wild-type character (red eye-color). This means that flies with two copies of the purple allele (the mutant form of the gene, which is designated pr) have purple eyes, but heterozygotes, flies with one copy of the purple allele and one copy of the wild-type allele (designated +), have normal wild-type eyes (as do flies with two copies of the wild-type allele). See Table 1.

To see how the classical theory explains trait transmission, consider a cross of red-eyed females with purple-eyed males that was carried out by Morgan's collaborators. The offspring all had red eyes. So the trait of red eyes was passed from the females to all their offspring even though the offspring's male parents had purple eyes. The classical explanation of this inheritance pattern proceeds, as do all classical explanations of inheritance patterns, in two stages.

The first stage accounts for the transmission of genes and goes as follows (Figure 1): each offspring received one copy of chromosome II from each parent. The maternally derived chromosomes must have contained the wild-type allele (since both second-chromosomes of every female parent used in the experiment contained the wild-type allele -- this was known on the basis of previous experiments). The paternally derived chromosomes must have contained the purple allele (since both second-chromosomes of every male parent contained the purple allele -- this was inferred from the knowledge that purple is recessive to red eye-color). Hence, all offspring were heterozygous (pr / +). Having explained the genetic makeup of the progeny by tracing the transmission of genes from parents to offspring, we can proceed to the second stage of the explanation: drawing an inference about phenotypic appearances. Since all offspring were heterozygous (pr / +), and since purple is recessive to wild-type, all offspring had red eye-color (the wild-type character). See Figure 1.

Notice that the reasoning here does not depend on identifying the material make-up, mode of action, or general function of the underlying gene. It depends only on the ideas that copies of the gene are distributed from generation to generation and that the difference in the gene (i.e., the difference between pr and +), whatever this difference is, causes the phenotypic difference. The idea that the gene is the difference maker needs to be qualified: differences in the gene cause phenotypic differences in particular genetic and environmental contexts. This idea is so crucial and so often overlooked that it merits articulation as a principle (Waters 1994):

Here is the original post:
Molecular Genetics (Stanford Encyclopedia of Philosophy)

Molecular genetics is the field of biology and genetics that studies the structure and function of genes at a molecular level. Molecular genetics employs the methods of genetics and molecular biology to elucidate molecular function and interactions among genes. It is so called to differentiate it from other sub fields of genetics such as ecological genetics and population genetics.

Along with determining the pattern of descendants, molecular genetics helps in understanding developmental biology, genetic mutations that can cause certain types of diseases. Through utilizing the methods of genetics and molecular biology, molecular genetics discovers the reasons why traits are carried on and how and why some may mutate.

One of the first tools available to molecular geneticists is the forward genetic screen. The aim of this technique is to identify mutations that produce a certain phenotype. A mutagen is very often used to accelerate this process. Once mutants have been isolated, the mutated genes can be molecularly identified.

Forward saturation genetics is a method for treating organisms with a mutagen, then screens the organism's offspring for particular phenotypes. This type of genetic screening is used to find and identify all the genes involved in a trait.[1]

While forward genetic screens are productive, a more straightforward approach is to simply determine the phenotype that results from mutating a given gene. This is called reverse genetics. In some organisms, such as yeast and mice, it is possible to induce the deletion of a particular gene, creating what's known as a gene "knockout" - the laboratory origin of so-called "knockout mice" for further study. In other words this process involves the creation of transgenic organisms that do not express a gene of interest. Alternative methods of reverse genetic research include the random induction of DNA deletions and subsequent selection for deletions in a gene of interest, as well as the application of RNA interference.

A mutation in a gene can result in a severe medical condition. A protein encoded by a mutated gene may malfunction and cells that rely on the protein might therefore fail to function properly. This can cause problems for specific tissues or organs, or for the entire body. This might manifest through the course of development (like a cleft palate) or as an abnormal response to stimuli (like a peanut allergy). Conditions related to gene mutations are called genetic disorders. One way to fix such a physiological problem is gene therapy. By adding a corrected copy of the gene, a functional form of the protein can be produced, and affected cells, tissues, and organs may work properly. As opposed to drug-based approaches, gene therapy repairs the underlying genetic defect.

One form of gene therapy is the process of treating or alleviating diseases by genetically modifying the cells of the affected person with a new gene that's functioning properly. When a human disease gene has been recognized molecular genetics tools can be used to explore the process of the gene in both its normal and mutant states. From there, geneticists engineer a new gene that is working correctly. Then the new gene is transferred either in vivo or ex vivo and the body begins to make proteins according to the instructions in that gene. Gene therapy has to be repeated several times for the infected patient to continually be relieved, however, as repeated cell division and cell death slowly randomizes the body's ratio of functional-to-mutant genes.

Currently, gene therapy is still being experimented with and products are not approved by the U.S. Food and Drug Administration. There have been several setbacks in the last 15 years that have restricted further developments in gene therapy. As there are unsuccessful attempts, there continue to be a growing number of successful gene therapy transfers which have furthered the research.

Major diseases that can be treated with gene therapy include viral infections, cancers, and inherited disorders, including immune system disorders.[citation needed]

Classical gene therapy is the approach which delivers genes, via a modified virus or "vector" to the appropriate target cells with a goal of attaining optimal expression of the new, introduced gene. Once inside the patient, the expressed genes are intended to produce a product that the patient lacks, kill diseased cells directly by producing a toxin, or activate the immune system to help the killing of diseased cells. [2]

Read more:
Molecular genetics - Wikipedia, the free encyclopedia

This article is about the general scientific term. For the scientific journal, see Genetics (journal).

Genetics is the study of genes, heredity, and genetic variation in living organisms.[1][2] It is generally considered a field of biology, but it intersects frequently with many of the life sciences and is strongly linked with the study of information systems.

The father of genetics is Gregor Mendel, a late 19th-century scientist and Augustinian friar. Mendel studied 'trait inheritance', patterns in the way traits were handed down from parents to offspring. He observed that organisms (pea plants) inherit traits by way of discrete "units of inheritance". This term, still used today, is a somewhat ambiguous definition of what is referred to as a gene.

Trait inheritance and molecular inheritance mechanisms of genes are still a primary principle of genetics in the 21st century, but modern genetics has expanded beyond inheritance to studying the function and behavior of genes. Gene structure and function, variation, and distribution are studied within the context of the cell, the organism (e.g. dominance) and within the context of a population. Genetics has given rise to a number of sub-fields including epigenetics and population genetics. Organisms studied within the broad field span the domain of life, including bacteria, plants, animals, and humans.

Genetic processes work in combination with an organism's environment and experiences to influence development and behavior, often referred to as nature versus nurture. The intra- or extra-cellular environment of a cell or organism may switch gene transcription on or off. A classic example is two seeds of genetically identical corn, one placed in a temperate climate and one in an arid climate. While the average height of the two corn stalks may be genetically determined to be equal, the one in the arid climate only grows to half the height of the one in the temperate climate, due to lack of water and nutrients in its environment.

The word genetics stems from the Ancient Greek genetikos meaning "genitive"/"generative", which in turn derives from genesis meaning "origin".[3][4][5]

The modern working definition of a gene is a portion (or sequence) of DNA that codes for a known cellular function or process (e.g. the function "make melanin molecules"). A single 'gene' is most similar to a single 'word' in the English language. The nucleotides (molecules) that make up genes can be seen as 'letters' in the English language. Nucleotides are named according to which of the four nitrogenous bases they contain. The four bases are cytosine, guanine, adenine, and thymine. A single gene may have a small number of nucleotides or a large number of nucleotides, in the same way that a word may be small or large (e.g. 'cell' vs. 'electrophysiology'). A single gene often interacts with neighboring genes to produce a cellular function and can even be ineffectual without those neighboring genes. This can be seen in the same way that a 'word' may have meaning only in the context of a 'sentence.' A series of nucleotides can be put together without forming a gene (non coding regions of DNA), like a string of letters can be put together without forming a word (e.g. udkslk). Nonetheless, all words have letters, like all genes must have nucleotides.

A quick heuristic that is often used (but not always true) is "one gene, one protein" meaning a singular gene codes for a singular protein type in a cell (enzyme, transcription factor, etc.)

The sequence of nucleotides in a gene is read and translated by a cell to produce a chain of amino acids which in turn folds into a protein. The order of amino acids in a protein corresponds to the order of nucleotides in the gene. This relationship between nucleotide sequence and amino acid sequence is known as the genetic code. The amino acids in a protein determine how it folds into its unique three-dimensional shape, a structure that is ultimately responsible for the protein's function. Proteins carry out many of the functions needed for cells to live. A change to the DNA in a gene can alter a protein's amino acid sequence, thereby changing its shape and function and rendering the protein ineffective or even malignant (e.g. sickle cell anemia). Changes to genes are called mutations.

The observation that living things inherit traits from their parents has been used since prehistoric times to improve crop plants and animals through selective breeding.[6] The modern science of genetics, seeking to understand this process, began with the work of Gregor Mendel in the mid-19th century.[7]

See more here:
Genetics - Wikipedia, the free encyclopedia

Public release date: 15-Oct-2012 [ | E-mail | Share ]

Contact: Jennifer Hilliard Scott jscott1@georgiahealth.edu 706-721-8604 Georgia Health Sciences University

AUGUSTA, Ga. Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

Drugs commonly used to treat those types of conditions called glucocorticoids work by turning down the body's anti-inflammatory response, but simultaneously turn on other pathways that lead to bone loss. The result can lead to osteoporosis and an accumulation of marrow fat, says Dr. Xingming Shi, bone biologist at the GHSU Institute of Molecular Medicine and Genetics.

The key to the body developing bone instead of fat, a small protein called GILZ, was shown in cell cultures in 2008. Now, with work by GHSU Graduate Student Guodong Pan, the work has been replicated in an animal model. Pan received the American Society for Bone and Mineral Research's Young Investigator Award for his work at the society's annual meeting Oct. 12-15 in Minneapolis.

Bone and marrow fat come from the same biological precursor mesynchymal stem cells. "The pathways for bone and fat have a reciprocal relationship, so we needed to find the key that disrupts the fat production pathway, which would then instead encourage bone growth," Shi says.

GILZ, Shi and Pan say, was already a known mediator of the anti-inflammatory response of glucocorticoids, and the protein also mediates bone production. Shi's early research had shown that glucocorticoids enhance bone formation in the lab because of a short "burst" of GILZ.

The protein works by inhibiting the way cells regulate fat production and turn on fat-producing genes, Shi says. "When you permanently express GILZ, the fat pathway is suppressed, so the body chooses to produce bone instead."

"We found that when we overexpressed the protein in these mice, it increased bone formation," Pan added. "This supports our original hypothesis that GILZ mediates the body's response to glucocorticoids and encourages bone growth." In fact, the genetically modified mice showed a significant increase in bone mineral density and bone volume as well, he found.

"That means GILZ is a potential new anti-inflammatory drug candidate that could spare people from the harmful effects associated with glucocorticoid therapy," Pan said

See the original post:
Protein could be key for drugs that promote bone growth

BOLOGNA, Italy--(BUSINESS WIRE)--

Silicon Biosystems, S.p.A., a provider of specialized molecular and cellular biology technologies, will present at the Fourth World Circulating Tumour Cells Summit, April 25, 2012 at 3:30 p.m. at the Maritim Hotel in Berlin. Dr. Nicol Manaresi, founder and chief technology officer of Silicon Biosystems, will provide an overview of the DEPArray system, which uses image-based single-cell sorting to deliver pure populations of rare tumor cells.

As part of the presentation, Dr. Manaresi will also offer recent data demonstrating single-CTC molecular characterization based on Whole Genome Amplification using the companys proprietary Ampli1 WGA kit followed by sequencing with Ion Torrent.

Silicon Biosystems is a device manufacturer leading the field in the detection and isolation of single cells for cancer research and prenatal genetic testing. The companys DEPArray technology exploits microelectronics and the principles of dielectrophoresis to find, sort, isolate, and collect 100 percent pure populations of rare cells, such as CTCs, for single-cell based genomic and transcriptional profiling.

The collection of pure individual CTCs from biological samples is a game changer in the quest to obtain clinical utility of these cells as it enables individual cell-based molecular profiling for personalized therapy, going beyond existing cell counting approaches for prognostic purposes, said Manaresi. We show that 100 percent pure single-CTC sorting by DEPArray and DNA amplification with our Ampli1 WGA seamlessly integrates with Ion Torrent AmpliSeq Cancer Panel sequencing to deliver a comprehensive overview of the mutational status, cell-by-cell, in a streamlined and automated manner. To the best of our knowledge, it is the first time this has been achieved.

There are multiple large and expanding market opportunities for technology that find and isolate rare cells for molecular analysis. Silicon Biosystems DEPArray is used for translational medicine applications in metastatic cancer, cardiovascular disease, prenatal genetics, and stem cells research.

The World CTC Summit attracts important members across the CTC study community including diagnosticians, drug developers, technology providers and clinicians, said Manaresi. Silicon Biosystems is eager to join our peers and share the excitement of this achievement, and the impact of our unique method for CTC collection and analysis for the advancement of patient diagnosis and decision making.

About Silicon Biosystems

Silicon Biosystems, Inc. was formed in October 2010 as a wholly owned subsidiary of Silicon Biosystems, S.p.A. based in Bologna, Italy. The company manufactures and sells the DEPArray platform which is based on the principle of dielectrophoresis to isolate and manipulate cells in suspension with a microelectronic array. The approach, patented by Silicon Biosystems, offers the unique ability to control individual cells and micro-particles inside a disposable cartridge. The DEPArray platform makes it possible to find, sort, select and separate individual cells for further analysis or culturing. For more information on Silicon Biosystems visit http://www.siliconbiosystems.com.

View original post here:
Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit

Scientists grow a rat lung in the laboratory

By LAURAN NEERGAARD (AP) – 4 days ago

WASHINGTON — It's an early step toward one day building new lungs: Yale University researchers took apart and regrew a rat's lung, and then transplanted it and watched it breathe.

The lung stayed in place only for an hour or two, as the scientists measured it exchanging oxygen and carbon dioxide much like a regular lung — but also spotted some problems that will take more research to fix.

Still, the work is a step in the science fiction-sounding hunt for ways to regenerate damaged lungs — although lead researcher Dr. Laura Niklason cautions that it may be 20 or 25 years before a build-a-new-organ approach is ready for people.

The work was reported online Thursday in the journal Science.

Nearly 400,000 people die of lung diseases each year in the U.S. alone, according to the American Lung Association, and lung transplants are far too rare to offer much help.

But how to replicate these spongy organs? Niklason's team stripped an adult rat's lung down to its basic structural support system — its scaffolding — to see if it's possible to rebuild rather than starting completely from scratch.

First, they essentially washed away the different kinds of cells lining that lung. It gradually faded from a healthy red to a white structure of mostly collagen and other connective tissue that maintained the shape and stretchiness of the original lung, even the tubes where airways would be.

This scaffolding is like a universal donor that shouldn't pose rejection problems, said Niklason: "Your collagen and my collagen are identical."

The researchers put the lung scaffolding into a bioreactor, an incubator-style container designed to mimic the environment in which fetal lungs develop, with fluid pumping through them.

Then they injected a mixture of different lung cells taken from a newborn rat. In the bioreactor, those cells somehow migrated to the right spots and grew air sacs, airways and blood vessels.

In short-term implants in four different rats, engineered lungs replaced one of the animals' native lungs and proved 95 percent as efficient at exchanging oxygen and carbon dioxide, Niklason said.

However, among the problems she spotted were small clots that formed inside the engineered lung, a sign that the new cells hadn't grown a thick enough cover in some places.

The biggest challenge: For this approach ever to work without a person's body rejecting the new tissue, scientists would need to use a recipient's own cells, Niklason explained. But there isn't a way yet to cull the kind of personalized stem cells that would be needed, meaning stem cell research must improve first, she said.

This overall approach also worked in a 2008 University of Minnesota experiment that grew a beating rat heart, and Minnesota researcher Dr. Doris Taylor welcomed the Yale lung work.

Separately in Science, a Harvard University team coated a flexible chip with layers of living lung cells, creating a laboratory tool that mimics some of the action of a breathing human lung. The goal: To replace some of the animal studies needed to test how lungs react to environmental toxins or inhaled drugs.

Online: http://www.sciencemag.org

(06-18) 13:42 PDT SAN FRANCISCO -- Dr. Shinya Yamanaka, a stem cell researcher at UCSF's Gladstone Institutes who discovered a technique for transforming adult skin cells into "pluripotent" stem cells without resorting to human embryos, has won Japan's $550,000 Kyoto Prize, an international award that honors scientific, cultural and spiritual contributions to human knowledge.

His discovery resulted in a class of much-sought stem cells that scientists can induce to become virtually any other type of functioning human cell that one day might be used to treat varied diseases or injuries.

During their research, Yamanaka and his colleagues altered the genetics of adult skin cells by inserting four specific viral genes that produce proteins known as transcription factors into the cells. Those proteins in turn yielded other genes that reprogrammed the skin cells so they acquired all the characteristics that made them what are now known as induced pluripotent cells.

Before his discovery, those pluripotent human stem cells could only be harvested from human embryos, a source posing such powerful ethical issues that former President George W. Bush banned virtually all embryonic stem cell research eight years ago. The ban remained in force until President Obama reversed it last year.

Yamanaka, 47, who is attending the annual meeting of the International Society of Stem Cell Research in San Francisco this week, was not told of his award until just before midnight Pacific time on Thursday.

The Kyoto Prize is awarded annually by Japan's Inamori Foundation for major discoveries in many fields of advanced technology, and four other Bay Area scientists have won it in recent years.

They are Leonard Herzenberg, a Stanford geneticist and immunologist who developed a revolutionary cell-sorting machine now crucial to advanced biomedical research; Alan Kay, a Silicon Valley pioneer at Hewlett-Packard who led advanced computing technology for 40 years; Donald E. Knuth, a Stanford information technology expert and specialist in computer programming, language analysis and computerized printing and Richard Karp, a UC Berkeley computer scientist and pioneer in computational biology.

In addition to heading his laboratory at the Gladstone Institute for Cardiovascular Research on the Mission Bay campus of UCSF, Yamanaka is also a professor at Kyoto University, where he began his efforts seeking a way of transforming adult cells.

Besides resolving ethical issues by his achievement, Yamanaka's success also means that the pluripotent stem cells needed to treat a patient's disease can be obtained from the ordinary skin cells of a patient's own body - thus making stem cell therapy possible without the hazards involved in immunologic rejection of cells from other people.

Robert Lanza, chief scientific officer of Advanced Cell Technology and an adjunct professor at Wake Forest University's stem cell research center, said recently that Yamanaka's work "is likely to be the most important stem cell breakthrough of all time."

"The ability to generate an unlimited supply of patient-specific stem cells will revolutionize the future of medicine," Lanza said.

Read more: http://www.sfgate.com